The good thing for CBRX is that the drug is already on the market and can be used off-label. We still have the ACOG/SMFM statement coming and they may be more generous in their assessments.
So far all they've done is tear apart efficacy with a very high standard of "could these results be due to chance". The AdCom meeting will allow more expression of all the costs of NOT using Prochieve if its efficacy is ignored. If ACOG/SMFM are positive at all it will push reasonable off-label use. CBRX should see about $0.16/share in related incremental royalties ($0.05/share US and $0.11/share Europe +ROW) if they can get 10% of the 1-2cm population with 1% of <1cm and 1% of 2-2.5cm. Given that CBRX has almost no costs and is already essentially breakeven...I'm thinking current pps is low.